ASC-J9 Suppresses Castration-Resistant Prostate Cancer Growth through Degradation of Full-length and Splice Variant Androgen Receptors  by Yamashita, Shinichi et al.
ASC-J9 Suppresses Castration-
Resistant Prostate Cancer
Growth through Degradation of
Full-length and Splice Variant
Androgen Receptors1,2
Shinichi Yamashita*,†,3, Kuo-Pao Lai*,3,
Kun-Lung Chuang*,‡,3, Defeng Xu*,
Hiroshi Miyamoto*, Tatsuo Tochigi§,
See-Tong Pang‡, Lei Li*, Yoichi Arai†,
Hsing-Jien Kung¶, Shuyuan Yeh*
and Chawnshang Chang*,#
*George Whipple Lab for Cancer Research, Departments
of Pathology, Urology, and Radiation Oncology, and
The Wilmot Cancer Center, University of Rochester Medical
Center, Rochester, NY, USA; †Department of Urology,
Tohoku University Graduate School of Medicine, Sendai,
Japan; ‡Department of Urology and Graduate Institute of
Clinical Medicine, Chang Gung University/Hospital,
Taoyuan, Taiwan; §Department of Urology, Miyagi Cancer
Center, Natori, Japan; ¶Department of Biological
Chemistry and Cancer Center, University of California
Davis Medical Center, Sacramento, CA, USA; #Sex
Hormone Research Center, China Medical University
and Hospital, Taichung, Taiwan
Abstract
Early studies suggested androgen receptor (AR) splice variants might contribute to the progression of prostate
cancer (PCa) into castration resistance. However, the therapeutic strategy to target these AR splice variants still
remains unresolved. Through tissue survey of tumors from the same patients before and after castration resis-
tance, we found that the expression of AR3, a major AR splice variant that lacks the AR ligand-binding domain,
was substantially increased after castration resistance development. The currently used antiandrogen, Casodex,
showed little growth suppression in CWR22Rv1 cells. Importantly, we found that AR degradation enhancer ASC-J9
could degrade both full-length (fAR) and AR3 in CWR22Rv1 cells as well as in C4-2 and C81 cells with addition of
AR3. The consequences of such degradation of both fAR and AR3 might then result in the inhibition of AR tran-
scriptional activity and cell growth in vitro. More importantly, suppression of AR3 specifically by short-hairpin AR3
or degradation of AR3 by ASC-J9 resulted in suppression of AR transcriptional activity and cell growth in
CWR22Rv1-fARKD (fAR knockdown) cells in which DHT failed to induce, suggesting the importance of targeting
AR3. Finally, we demonstrated the in vivo therapeutic effects of ASC-J9 by showing the inhibition of PCa growth
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using the xenografted model of CWR22Rv1 cells orthotopically implanted into castrated nudemice with undetectable
serum testosterone. These results suggested that targeting both fAR- and AR3-mediated PCa growth by ASC-J9 may
represent the novel therapeutic approach to suppress castration-resistant PCa. Successful clinical trials targeting both
fAR and AR3 may help us to battle castration-resistant PCa in the future.
Neoplasia (2012) 14, 74–83
Introduction
Prostate cancer (PCa) is currently the second leading cause of death in
men in the United States [1]. Androgen deprivation therapy (ADT)
has been the standard treatment for patients with advanced PCa since
Huggins and Hodges [2] reported the castration effect on PCa. ADT
is initially effective to inhibit the growth of androgen-dependent PCa
and suppresses tumor progression in most PCa patients; however, most
patients treated with current ADT eventually progress with castration-
resistant PCa (CRPC) within 1 to 2 years [3,4]. The mechanisms
underlying castration-resistant androgen receptor (AR)–mediated sig-
naling remain unclear, although several possible mechanisms have been
proposed [5–11].
One proposed mechanism involves the AR splice variants, espe-
cially AR3 (also named as AR-V7) that lacks the portion of the ligand-
binding domain (LBD) [8,9], which have been reported to transactivate
AR-targeted genes in the absence of androgen [7–10,12]. Interestingly, a
recent report from Watson et al. [12] indicated that such constitutively
active AR splice variants (AR-V7) might require full-length AR (fAR).
They demonstrated that the growth of LNCaP cells with AR-V7 over-
expression was suppressed after MDV3100 (a new antiandrogen) treat-
ment or using small interfering RNA to target fAR. These findings raised
an interesting question as to whether those AR splice variants have any
translational or clinical value to target.
We report here that AR3 might represent an important target to
suppress owing to its roles at selective stage(s) of PCa progression.
Furthermore, we demonstrated that AR degradation enhancer,
ASC-J9, was able to degrade both fAR and AR3 that resulted in
the suppression of AR-targeted genes expression and cell growth in
several CRPC cells.
Materials and Methods
Cells, Reagents, and Human Prostate Specimens
Human PCa cells CWR22Rv1, CWR22Rv1-fARKD (knockdown
of fAR [13]), C4-2, and C81 were used. The antibodies for AR
(N-20) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were
Figure 1. Little suppressive effect of Casodex on CRPC cells with AR3 expression. (A) AR expression in CRPC cell lines. Cell lysates of
C81, C4-2, and CWR22Rv1 (22Rv1) cells were immunoblotted with anti-AR and anti-GAPDH. (B) AR3 expression in C81/AR3 and C4-2/AR3
cells. C81 and C4-2 cells were infected with lentiviral vector pWPI/AR3 and the expression of AR3 was confirmed by Western blot analysis.
(C) Effect of Casodex on cell growth. CWR22Rv1 (left panel), C4-2/Vector (middle panel), and C4-2/AR3 (right panel) cells were treated with
5 or 10 μM Casodex, and the cell growth was examined by MTT assay. Data presented are from at least three independent experiments.
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purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The
antibody for AR-V7 was kindly provided by Dr Jun Luo [8]. ASC-J9
(5-hydroxy-1,7-bis(3,4-dimethoxyphenyl)-1,4,6-heptatrien-3-one),
also named as dimethylcurcumin, was a gift from AndroScience
(San Diego, CA), and bicalutamide (Casodex) was purchased from
AstraZeneca (Wilmington, DE). Plasmids containing AR3 comple-
mentary DNA and short hairpin RNAs specific for AR3 (shAR3)
were kindly provided by Dr Yun Qiu [9]. Human primary prostate
tissues were collected from the same patients before ADT and after
development to CRPC at Tohoku University Hospital ( Japan),
Miyagi Cancer Center (Japan), and Chang Gung Memorial Hospital
(Taiwan). These patients underwent transrectal prostate needle biopsy
or transurethral resection of the prostate. This study has been approved
by the ethics committee of the three institutions (Tohoku University
Hospital, Miyagi Cancer Center, and Chang Gung Memorial Hos-
pital), and informed consent was obtained from each patient. The
patients’ characteristics (age, prostate-specific antigen [PSA] level,
Gleason score, stage, and time to develop CRPC) and outcomes (sam-
ple harvest after progression to CRPC, survival time after ADT, and the
current status of alive or death) are summarized in Table W1.
Western Blot Analysis, Quantitative Real-time Polymerase
Chain Reaction, and Luciferase Reporter Assay
Cells were cultured and treated with or without ASC-J9 for 24 hours
in 10% charcoal-dextran-stripped fetal bovine serum (CD-FBS) media.
Cell lysates were harvested and subjected to Western blot analysis.
Quantitative real-time polymerase chain reaction (qPCR) was performed
in triplicate with a Bio-Rad iCycler system (Bio-Rad, Hercules, CA);
and messenger RNA (mRNA) levels of PSA, TMPRSS2, FKBP5, and
GAPDH were measured. Cells were transiently transfected with mouse
mammary tumor virus luciferase reporter (MMTV-Luc) or ARE4-Luc
plus pRL-TK as internal control. Luciferase activities were measured
using GloMax 20/20 Luminometer (Promega, Madison, WI).
Cell Growth Assay
Cells were treated with vehicle, 1 nM dihydrotestosterone (DHT),
5 μM Casodex, and 5 or 10 μM ASC-J9 in 10% CD-FBS medium.
The media were replenished every other day, and we followed the
standard MTT assay protocol.
Immunohistochemical Analysis
The paraffin-embedded tissue sections were stained with anti–AR-
V7 and counterstained with hematoxylin. These staining signals were
manually evaluated by a pathologist (H.M.) blinded to patient identity.
Each sample was classified with negative, weak, moderate, and strong
expression based on intensity score and the percentage of immuno-
reactive cells [14].
In Vivo Tumor Growth Assay
Animal procedures were conducted in accordance with the protocol
approved by the University of Rochester Committee on Animal Re-
sources. CWR22Rv1 cells (1 × 106 cells per site) were injected into both
anterior prostates (orthotopic) of castrated nude mouse after 2 weeks of
implantation. The mice were randomly divided into two groups (four
mice/eight tumors each group) and either received 75 mg/kg ASC-J9
intraperitoneal injection or vehicle control every other day. After 4 weeks
Figure 2. Increased AR3 expression in CRPC of human PCa speci-
mens. (A) Human prostate tumor tissues of the same patient were
immunostained with specific AR3 (AR-V7) antibody. Representative
data shown are from six pairs of patients before and after ADT. Scale
bar, 50 μm. (B) The immunoreactive score of AR3 expression was
determined. Six paired human prostate tissues were evaluated and
represented by negative, weak, moderate, and strong expression as
0, 1, 2, and 3, respectively. *P < .05 and **P < .01, Student’s t test.
Figure 3. ASC-J9 suppresses AR-targeted genes, AR transactivation, and cell growth through AR degradation in CRPC cells. (A) Degradation
of fAR and AR3 by ASC-J9. CRPC cells were treated with 5, 7.5, and 10 μM ASC-J9 in the presence or absence of 1 nM DHT for 24 hours.
The expression of fAR and AR3 was evaluated by Western blot analysis in C81 (upper panel), C4-2 (middle panel), CWR22Rv1 (lower panel),
and CWR22Rv1-fARKD (bottom panel). (B) Reduction of AR-targeted gene expression after ASC-J9 treatment. C81, C4-2, CWR22Rv1, and
CWR22Rv1-fARKD cells were treatedwith 10 μMASC-J9. The expressions of AR-targeted genes PSA (upper panel), TMPRSS2 (middle panel),
and FKBP5 (lower panel) were determined by real-time PCR analysis. (C) Suppressive effect of ASC-J9 on AR transactivation in CRPC cells.
AR transactivational activity was monitored by transfection of MMTV-Luc (upper panel) or ARE4-Luc (lower panel) into C81, C4-2, and
CWR22Rv1 cells and treatingwith 10 μMASC-J9. The results were normalized to Renilla luciferase and presented as fold difference between
groups. (D) Effect of ASC-J9 on cell growth was determined by MTT assay. (E) Elevated cell cycle regulators p21 and p27 in ASC-J9–treated
CWR22Rv1 cells leading to inhibition of cell growth. The expressions of fAR/AR3, proliferating cell nuclear antigen (PCNA), p21, p27, and
GAPDH were evaluated by Western blot analysis. Data presented are from at least three independent experiments.
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of treatment, all mice were killed to examine the tumor growth. Body
weights and mice activity were measured weekly.
Statistical Analysis
All values are presented as mean ± SEM. Statistical analyses and
comparisons among groups were performed using Student’s t test
(2-tailed). P < .05 was considered statistically significant.
Results
Casodex Has Little Effect on Growth of
Castration-Resistant PCa Cell Lines
We first surveyed AR3 expression in various castration-resistant
human PCa cell lines and found that the expression amount of AR3
(80 kDa) was very low in C81 and C4-2 cells but was abundant in
CWR22Rv1 cells (Figure 1A). The identification of AR3 splice variant
was confirmed with specific AR-V7 antibody (data not shown). To fur-
ther examine the effect of AR3-mediated PCa cell growth, we then
stably infected AR3 into C4-2 and C81 cells (named C4-2/AR3 and
C81/AR3), respectively (Figure 1B). We found that C4-2/AR3 cells
showed elevated cell growth compared to C4-2/Vector in the androgen-
free condition (Figure 1C ) as well as in C81/AR3 cells (data not
shown). Importantly, Casodex treatment resulted in little suppressive
effects on CWR22Rv1 and C4-2/AR3 cells (Figure 1C ). These data
suggested that AR3 might play important roles for PCa progression at
some selective stages and Casodex might have little impact to suppress
AR3-mediated PCa cell growth.
Increased AR3 Expression in Human PCa Specimens of the
Same Patient after CRPC Development
To evaluate the changes of AR3 expression correlated with PCa
progression, we surveyed six paired human PCa specimens before
ADT and after development of castration resistance. Four specimens
before ADT displayed benign prostate gland structure and AR3 expres-
sion was almost undetectable in benign prostate glands (Figure 2A, left).
AR3 expression was weakly positive in PCa cells before ADT
(Figure 2A, middle); however, there is a significant increase of AR3
expression after development into castration resistance (Figure 2, A and
B, and Table W1), which is in agreement with previous studies [8,9].
ASC-J9 Degrades fAR and AR3 in PCa Cells
Because Casodex failed to suppress AR3-mediated cell growth, we were
interested to test the therapeutic effects of ASC-J9. ASC-J9 was identified
as a new AR degradation enhancer that could promote AR degrada-
tion [15–17] by disrupting the interaction between AR and selective AR
coregulators [18], mainly in prostate stromal and/or luminal epithelial
cells, resulting in the suppression of AR transactivation (Chang et al.,
unpublished data). We also found ASC-J9 had little effect on other
steroid receptors, such as glucocorticoid receptor, estrogen receptor α,
and retinoid X receptor α [16]. It is noteworthy to reiterate that the ac-
tion of ASC-J9 is different from those currently available antiandrogens
or a recently developed antiandrogen, MDV3100, which prevents andro-
gens from binding to the LBD of AR. More importantly, mice treated
with ASC-J9 retained normal sexual function and fertility [16].
We then determined the effects of ASC-J9 on the expression of
fAR and AR3 in C81, C4-2, CWR22Rv1, and CWR22Rv1-fARKD
cells. We found that ASC-J9 was able to degrade fAR and AR3 in a
dose-dependent manner in various human PCa cells (Figure 3A). The
nuclear and cytoplasmic extracts from ASC-J9–treated CWR22Rv1 cells
were collected to determine compartmentalized fAR/AR3 expression levels.
The results showed that 1 nM DHT could promote fAR nuclear trans-
location and cotreatment of ASC-J9 could inhibit such nuclear trans-
location (Figure W1A). AR3 predominantly located in the nuclear
compartment and ASC-J9 could also inhibit its amounts (Figure W1A).
In contrast, MDV3100 failed to degrade fAR and AR3 in
CWR22Rv1 cells (Figure W2A). Furthermore, we examined the
mRNA of fAR and AR3 in CWR22Rv1 cells after ASC-J9 treatment
and found that there are few changes compared with vehicle- or
DHT-treated group (Figure W2B), suggesting that ASC-J9 mainly
targets AR protein degradation.
Next, we examined the effects of ASC-J9 on fAR- and AR3-
mediated targeted gene expression. One nanomolar of DHT, the
androgen concentration of human prostate tissue after ADT [19], could
induce the expression of AR-targeted genes (PSA, TMPRSS2, and
FKBP5) in C81, C4-2, and CWR22Rv1 cells but not in CWR22Rv1-
fARKD cells (Figure 3B). Addition of ASC-J9 could then suppress 1 nM
DHT-induced AR-targeted gene expression in these three cell lines
(Figure 3B). Moreover, ASC-J9 could also effectively suppress AR-
targeted genes in CWR22Rv1-fARKD cells (Figure 3B), suggesting
that ASC-J9 could also degrade AR3 resulting in suppressed AR3-
mediated transcription activity. Interestingly, we also found that ASC-J9
was able to inhibit AR3 target genes Akt1 [9] and c-Myc [20] in
CWR22Rv1 and CWR22Rv1-fARKD cells (Figure W3A). The qPCR
primer sequences of AR canonical-targeted genes (PSA, TMPRSS2, and
FKBP5), AR3-targeted genes (Akt1 and c-Myc), AR, and AR3 are pro-
vided in Figure W4. Using MMTV and ARE4 luciferase assays, AR
transactivational activity was suppressed by ASC-J9 treatment in the
presence of 1 nM DHT (Figure 3C).
We also assessed the growth effects of C81, C4-2, and CWR22Rv1
cells with 5 or 10 μM ASC-J9 treatments. The results showed that
1 nM DHT can promote cell growth and ASC-J9 significantly sup-
pressed the DHT-induced cell growth in all three PCa cell lines
(Figure 3D). We also observed that ASC-J9 displayed better growth
suppression than MDV3100 did in CWR22Rv1 cells (Figure W2C).
More importantly, treatment with 5 μM ASC-J9 did not inhibit the
cell growth of AR-negative cells (PC-3 and DU-145) (Chang et al.,
unpublished observations, 2012).
In contrast, although 1 nM DHT failed to induce cell growth in
CWR22Rv1-fARKD cells, ASC-J9 could still significantly suppress its
growth (Figure 3D, right). The potential mechanisms underlying the
antiproliferative effects of ASC-J9 were determined using Western blot
analysis to detect proliferationmarker (proliferating cell nuclear antigen)
and cyclin-dependent kinase inhibitors p21 and p27, suggesting that
ASC-J9 may use the up-regulation of p21 and p27 to inhibit the cell
growth in CWR22Rv1 cells (Figure 3E). The results were further con-
firmed using CWR22Rv1-fARKD cells with ASC-J9 treatment (Fig-
ure W5A), suggesting that targeting fAR either by shRNA or ASC-J9
could upregulate p27 expression leading to suppressed AR-mediated
cell growth, yet degradation of AR3 in CWR22Rv1-fARKD cells did
not display the significant changes of p27 expression (Figure W5A).
Together, results from Figures 3 andW3A suggested that, although
1 nM DHT failed to induce AR-mediated targeted genes expression
and cell growth in CWR22Rv1-fARKD cells, the existence of AR3
and those AR3-targeted genes could still play important roles to main-
tain cell growth in CWR22Rv1-fARKD cells. Addition of ASC-J9 to
degrade AR3, which resulted in the suppression of those AR3-targeted
genes and cell growth in CWR22Rv1-fARKD cells, not only pointed
out the important contribution of AR3 in PCa progression but also
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Figure 4. ASC-J9 suppresses AR-targeted genes and cell growth by degradation of fAR and ectopic AR3 in C81 and C4-2 cells.
(A) Determination of fAR and AR3 expression after ASC-J9 treatment. C81 and C4-2 cells infected with pWPI/AR3 or vector alone were
treated with 10 μM ASC-J9 and vehicle or 1 nM DHT for 24 hours. AR expression was evaluated by Western blot analysis. (B) Expres-
sions of AR-targeted genes in AR3 overexpressed cells. C81 and C4-2 cells with ectopically expressed AR3 were treated with ASC-J9.
The expressions of AR-targeted genes, such as PSA, TMPRSS2, and FKBP5, were evaluated by real-time PCR. (C) Effects of ASC-J9 on
cell growth of C81/Vector, C81/AR3, C4-2/Vector, and C4-2/AR3 cells were examined by MTT assay. Data presented are from at least
three independent experiments.
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clearly showed that ASC-J9 treatment could suppress both fAR- and
AR3-mediated transcriptional activity and growth in PCa cells.
ASC-J9 Suppresses AR-Targeted Genes and Cell Growth
in C81/AR3 and C4-2/AR3 Cells
In addition to studying the impacts of ACS-J9 on the endogenous
AR3 in CWR22Rv1 cells, we further validated AC-J9 can degrade AR3
and demonstrated this by ectopically delivering AR3 into C81 and
C4-2 cells (Figure 4A). We found that the level of those AR-targeted
gene expressions is elevated after adding AR3 and that 1 nMDHT treat-
ment further potentiates the AR-targeted gene expressions (Figure 4B).
As expected, ASC-J9 could degrade both endogenous fAR and over-
expressed AR3 in both C81/AR3 and C4-2/AR3 cells (Figure 4A).
This led to the suppression of 1 nM DHT-induced AR-targeted genes
expression (Figure 4B) and cell growth in these AR3-overexpressed cells
(Figure 4C).
AR3 Plays a Critical Role to Promote Cell Growth and
AR-Targeted Gene Expression in CWR22Rv1/
CWR22Rv1-fARKD Cells
To further confirm whether AR3 contributes to cell growth at
castration conditions, the lentivirus carrying shAR3 or scrambled con-
trol was transduced into CWR22Rv1 and CWR22Rv1-fARKD cells
to specifically suppress AR3 expressions (Figure 5A). As shown in
Figures 5B and W6A, shAR3 could suppress AR- and AR3-targeted
genes, respectively, as well as cell growth in CWR22Rv1 cells (Fig-
ure 5C ). Importantly, we found that shAR3 could also suppress
AR-targeted genes and cell growth in CWR22Rv1-fARKD cells. These
results are similar to ASC-J9 treatment in CWR22Rv1-fARKD cells
(Figure 3), suggesting that AR3 itself is important to maintain PCa cells
growth in such castration conditions.
Collectively, these results of Figures 3 to 5 suggested that AR3 by
itself might contribute to the AR-targeted gene expression and AR-
mediated PCa cell growth, and ASC-J9 could inhibit both fAR- and
AR3-mediated gene expression and cell growth in various CRPC cells.
ASC-J9 Suppresses Tumor Growth of CWR22Rv1 Cells
in Castrated Mice
Based on the previously mentioned results, we further evaluated
the effects of ASC-J9 in vivo, especially at the castration-resistant
stage. We found that even with complete ADT in mice through sur-
gical castration, the orthotopically implanted CWR22Rv1 cells with
vehicle treatment were still able to grow into tumors of significant size
(Figure 6A). However, mice treated with ASC-J9 had relative smaller
tumors compared to those with vehicle injection (Figure 6A). We also
Figure 5. Knocking-down AR3 suppresses AR-targeted genes and cell growth in CWR22Rv1 and CWR22Rv1-fARKD cells. (A) Reduction
of AR3 expression after delivery of shAR3. We evaluated the shAR3 knockdown efficiency by Western blot analysis in CWR22Rv1 and
CWR22Rv1-fARKD cells. (B) Examination of AR-targeted gene expressions after AR3 knockdown. CWR22Rv1 and CWR22Rv1-fARKD
cells with scramble control or shAR3 expression were used to detect AR-targeted gene expression by real-time PCR. (C) Effect of AR3
on cell growth of CWR22Rv1 and CWR22Rv1-fARKD cells. CWR22Rv1 and CWR22Rv1-fARKD cells infected with control (solid line) or
shAR3 (dashed line) were treated with 1 nM DHT and ASC-J9 followed by MTT cell growth assay. Data presented are from at least three
independent experiments.
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Figure 6. Therapeutic effect of ASC-J9 in vivo. (A) Evaluation of tumor volumes of CWR22Rv1 xenografts after ASC-J9 treatment.
CWR22Rv1 cells were implanted into anterior prostates of castrated nude mice (four mice each group) and ASC-J9 was intraperitoneally
injected for 4 weeks. Orthotopic tumors were harvested (eight tumors each group). Tumor volumes were measured and presented as
mean ± SEM. Comparison among groups was performed using Student’s t test. (B) Body weight determination during ASC-J9 treat-
ment. Body weights were weekly measured in vehicle- or ASC-J9–injected mice. (C) Histologic examination of tumor tissues after ASC-
J9 treatment. The tissues of xenografted tumors were processed by hematoxylin-eosin (HE) staining and immunohistochemical staining
for AR, Ki67, and TUNEL. Representative data shown are from four tumors in the ASC-J9 and control groups. Arrows indicate TUNEL-
positive cells. Scale bar, 50 μm. (D) Decreased AR expression of CWR22Rv1-xenografted tumors after ASC-J9 treatment. Proteins were
harvested from three tumors of each group. AR expression was evaluated by Western blot analysis. (E) Quantification of Ki67 and
TUNEL-positive cells in xenografted tumors. The ratio of immunostained positive cells (%) was calculated by the formula: (the number
of positive cells/total number of counted cells) × 100. Comparisons among groups were performed using Student’s t test.
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found that the body weight was comparable in mice either from
vehicle control or ASC-J9–treated (Figure 6B), suggesting little appar-
ent adverse event of ASC-J9.
We performed immunostaining with anti-AR antibody on tumors
and found that the AR intensity was reduced in ASC-J9–treated
tumors (Figure 6C ). Western blot analysis further confirmed that
ASC-J9 could degrade both fAR and AR3 in these xenografted tumors
in vivo (Figure 6D). In addition, Ki67 staining showed that ASC-J9–
treated tumors had significantly decreased Ki67-positive cells (Figure 6,
C and E [upper panels]). Finally, TUNEL assay also showed ASC-J9–
treated tumors displayed increased apoptotic cells, which may also
contribute to tumor growth suppression of these xenografts (Figure 6,
C [arrows] and E [lower panel ]).
Together, results from Figure 6A to E demonstrated that ASC-J9
treatment might represent the first therapeutic approach that could
further suppress CRPC growth in complete androgen-deprived con-
ditions through degradation of fAR and AR3.
Discussion
CWR22 xenografted tumor was established from human primary pros-
tate tumor in the patient with bone metastases [21,22]. CWR22Rv1 is
a CRPC cell line derived from the CWR22R subline, which was iso-
lated from the recurrent tumor of the androgen-dependent CWR22
cells in castrated mice [23,24]. The origin of CWR22Rv1 cells was dif-
ferent from other CRPC cell lines, such as C4-2 or C81, that were from
metastatic lymph nodes of mice xenografted with human PCa cell line,
LNCaP [25–28]. CWR22Rv1 expresses an exon 3–duplicated fAR in
addition to the multiple spliced forms [7–9,29]. Recent studies [30]
revealed a duplicated AR locus mediated by repetitive elements, which
may account for the aberrantly spliced forms of AR. The truncated re-
ceptor has been suggested to be derived from two possible pathways,
the aberrant splicing as is the case for AR3 and protease cleavage of
exon 3–duplicated fAR [29,31]. A different CWR22-derived relapsed
cell line, CWR22R1 [32], also displayed abundant truncated AR [9].
Thus, in the evolution of CRPC such as with CWR22, receptor trun-
cation typified by AR3 seems to be a dominant underlying mechanism.
Although the detailed truncation points may be different, most the
reported species lack the LBD, and are expected not to respond to
androgen and antiandrogens. As such, drugs which target the LBD
may not work as effectively. The present study is designed to investi-
gate the efficacy of drugs that target degradation of both fAR and the
truncated receptor.
In this study, we used various PCa cell lines, including C81, C4-2, and
CWR22Rv1 cells, as well as C81/AR3, C4-2/AR3, and CWR22Rv1-
fARKD cells to study AR3 in vitro function. The expression level of
fAR and AR3 in these PCa cells was different: in C81 and C4-2 cells,
most AR expression was fAR (fAR⋙ AR3). In C81/AR3 and C4-2/
AR3 cells, fAR expression level was equivalent to AR3 (fAR = AR3). In
contrast, AR3 expression level was higher than fAR (fAR < AR3) in
CWR22Rv1 cells, but most AR expression was AR3 in CWR22Rv1-
fARKD cells (fAR⋘ AR3). By characterizing these various PCa cells
with differential expression ratios of fAR to AR3, we concluded that
AR3 plays a critical role to promote PCa cell growth at some selective
stages, which is similar to early findings showing that overexpression of
AR3 in LNCaP cells promoted the cell growth [9]. Furthermore, our
data showed DHT-induced AR-targeted genes were obviously en-
hanced with addition of AR3 in C81 and C4-2 cells, suggesting that
AR3 might be able to cooperate with fAR to promote DHT-induced
AR-targeted genes. This is in agreement with a previous report showing
that constitutively active AR splice variants (AR-V7) required fAR to
promote AR-targeted genes and cell growth in LNCaP cells in the pres-
ence of androgen [12].
However, our data also showed that cell growth of CWR22Rv1-
fARKD was substantially increased compared to that of CWR22Rv1
cells under androgen-free conditions. Specifically knocking down
AR3 in CWR22Rv1 and CWR22Rv1-fARKD cells resulted in sig-
nificant growth inhibition, suggesting that AR3 might have dual roles:
AR3 by itself might be able to promote PCa cell growth particularly in
the absence of androgen at some selective PCa stages and the other
role is that AR3 could cooperate with fAR to modulate AR-targeted
genes and cell growth in the presence of androgen at many other PCa
stages. These conclusions strengthened our central hypothesis and led
us to believe that it is necessary to target both fAR and AR3 to have
better therapeutic efficacy, especially at castration-resistant stages when
AR3 expression is increased.
We demonstrated that Casodex failed to suppress the cell growth of
CWR22Rv1 cells, which is in agreement with an early report showing
that flutamide, another antiandrogen, had little suppressive effect on
the transactivation of ARv567es (another AR splice variant with deletion
of AR exon 5-7 regions) [10]. In this present study, we provided a new
therapeutic approach through using ASC-J9, which was able to degrade
both fAR and AR3 leading to the suppression of their mediated targeted
genes and cell growth in various CRPC cells in vitro and in vivo.
In conclusion, our data suggest that AR3 may have its essential roles
to promote PCa growth at selective PCa stages and targeting both fAR-
and AR3-mediated cell growth through ASC-J9 may become a new
useful therapeutic strategy to target PCa cells, which express AR splice
variants such as AR3.
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Supplementary Methods
Cell and Reagents
Human PCa cell lines CWR22Rv1 and CWR22Rv1-fARKD were
used. The antibodies for AR (N-20), PARP-1, α-tubulin, p27, and
GAPDH were purchased from Santa Cruz Biotechnology. MDV3100
was purchased from SelleckChem (Houston, TX) and ASC-J9
(5-hydroxy-1,7-bis(3,4-dimethoxyphenyl)-1,4,6-heptatrien-3-one) is a
gift from AndroScience. The NE-PER nuclear and cytoplasmic extrac-
tion reagents purchased from Thermo Scientific (Rockford, IL) were
used to separate nuclear and cytoplasmic fractions.
Cell Growth Assay
Cells were treated with vehicle, 1 nMDHT, 10 μMASC-J9, and 5 or
10 μM MDV3100 in 10% CD-FBS medium. The media were replen-
ished every other day, and we followed the standardMTT assay protocols.
Western Blot Analysis and Quantitative Real-time PCR
Cells were cultured and treated with or without 10 μMMDV3100 or
10 μMASC-J9 for 24 hours in 10% CD-FBS medium. Cell lysates were
harvested and subjected to Western blot analysis. Quantitative real-time
PCR (qPCR) was performed in triplicate with a Bio-Rad iCycler system,
andmRNA levels of fAR, AR3, Akt1, c-Myc, andGAPDHwere measured.
Table W1. Characteristics and Outcomes of Six Patients in the AR3 Immunohistochemical Staining.
Case Age (y) PSA (ng/ml) GS Stage Time to CRPC (mo) AR3 Staining Point of Sample Harvest* (mo) Survival from ADT (mo) Status
Benign PCa CRPC
1 70 190 4 + 4 T4 N1 M1 6 Neg Neg Mod 6 15 Death
2 79 37 3 + 5 T4 N1 M1 13 Neg Weak Mod 19 24 Death
3 73 160 4 + 4 T3b N0 M1 18 Weak Weak 48 61 Death
4 68 8550 4 + 5 T4 N0 M1 28 Weak Mod 37 62 Death
5 86 15 5 + 4 T3b N1 M1 30 Neg Weak Weak 43 70 Alive
6 66 1500 4 + 4 T3c N0 M1 26 Neg Weak Weak 65 93 Death
Death indicates death from cancer; GS, Gleason score; Mod, moderate; Neg, negative.
*Point of sample harvest after progression to CRPC.
Figure W1. ASC-J9 suppresses nuclear fAR and AR3 localization in CWR22Rv1 cells. CWR22Rv1 cells were treated with vehicle, 1 nM
DHT, 10 μM ASC-J9, or 1 nM DHT + 10 μM ASC-J9 and subjected to nuclear/cytoplasmic fraction separation. The extracts were used to
performed Western blot analysis against AR, PARP-1 (nuclear extract control), and α-tubulin (cytoplasmic extract control). Data pre-
sented are from at least three independent experiments.
Figure W2. ASC-J9, but not MDV3100, can degrade fAR and AR3 in CWR22Rv1 cells. (A) CWR22Rv1 cells were treated with vehicle, 1 nM
DHT, 10 μMMDV3100, or 1 nM DHT + 10 μMMDV3100, 10 μM ASC-J9, or 1 nM DHT + 10 μM ASC-J9 and then subjected to Western
blot analysis. The expressions of fAR, AR3, and GAPDH were determined. (B) The fAR and AR3 mRNA was determined by using quan-
titative PCR analysis. (C) ASC-J9 showed better growth inhibition than MDV3100 in CWR22Rv1 cells by using MTT assay. Data presented
are from at least three independent experiments.
Figure W3. ASC-J9 inhibits AR3 target genes Ak1 and c-Myc
expression in CWR22Rv1 and CWR22Rv1-fARKD cells. CWR22Rv1
and CWR22Rv1-fARKD cells were treated with vehicle, 1 nM DHT,
10 μMASC-J9, or DHT+ 10 μMASC-J9 and then subjected to qPCR
analysis. The expressions of Akt1 and c-Myc were determined and
normalized with GAPDH. Data presented are from at least three
independent experiments.
Figure W4. Primer sequences used for quantitative PCR analysis.
Figure W5. Targeting fAR, but not AR3, can upregulate p27 expres-
sion. ASC-J9 treatment on CWR22Rv1-fARKD cells did not reveal
the significant changes in p27 amounts.
Figure W6. Knocking down AR3 reduces Akt1 and c-Myc expres-
sion in CWR22Rv1 cells. Examination of AR3-targeted gene (Akt and
c-Myc) expressions after AR3 knockdown. CWR22Rv1 cells with
control or shAR3 expression were used to determine Akt1 and c-Myc
expressions using Q-PCR analysis. Data presented are from at least
three independent experiments.
